S1PR1 and lung disorder: Ozanimod is a novel oral sphingosine-1-phosphate (S1P) receptor ligand (SRL) that binds selectively to the S1P 1 and 5 receptors (S1P1, S1P5).1, 2, 3 SRLs, including S1P1-specific ligands, have been determined to be able to reduce lung inflammation in various lung-disease models.4, 5, 6